This study updates previous reports by the population-based Muscular Dystrophy Surveillance, Tracking and Research Network on associations between increased corticosteroid use over time, and delayed use of corticosteroids among non-Hispanic Black males and those having a positive family history of Duchenne muscular dystrophy. Data for 373 males from six sites born and followed during 2000-2015 were analyzed using Kaplan-Meier curve estimation and Cox proportional hazards modeling. Corticosteroids were offered to 75.6% of all males; 68.9% initiated use at median ages of 6.8 (offered) and 7.2 (used). The previously observed associations persisted. Further examination of these associations suggest diagnosis timing may partially account for the observed delays due to later diagnosis among non-Hispanic Black males and early diagnosis among those with a positive Duchenne muscular dystrophy family history. Further research into health inequities underlying diagnostic delays among non-Hispanic Black males and the safety profile of early corticosteroid use will further inform on variability in corticosteroid treatment.
EmeryAE. The muscular dystrophies. Lancet (London, England). 2002;359(9307):687–695.
2.
BlakeDJWeirANeweySEDaviesKE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev.2002;82(2):291–329.
3.
PassamanoLTagliaAPalladinoA, et al.Improvement of survival in Duchenne muscular dystrophy: retrospective analysis of 835 patients. Acta Myol. 2012;31(2):121–125.
4.
KienyPCholletSDelalandeP, et al.Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper Centre between 1981 and 2011. Ann Phys Rehabil Med.2013;56(6):443–454.
5.
SzaboSMSalhanyRMDeightonAHarwoodMMahJGoochKL. The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systematic literature review. Orphanet J Rare Dis.2021;16(1):237.
6.
BirnkrantDJBushbyKBannCM, et al; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol.2018;17(4):347–361.
7.
BirnkrantDJBushbyKBannCM, et al; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol.2018;17(3):251–267.
8.
BirnkrantDJBushbyKBannCM, et al; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol.2018;17(5):445–455.
9.
GriggsRCHerrBERehaA, et al.Corticosteroids in Duchenne muscular dystrophy: major variations in practice. Muscle Nerve.2013;48(1):27–31.
10.
MatthewsDJJamesKAMillerLA, et al.Use of corticosteroids in a population-based cohort of boys with Duchenne and Becker muscular dystrophy. J Child Neurol. 2010;25(11):1319–1324.
11.
FoxDJKumarAWestNADiRienzoAGJamesKAOleszekJ. Trends with corticosteroid use in males with Duchenne muscular dystrophy born 1982-2001. J Child Neurol.2015;30(1):21–26.
12.
WardLMKinnettKBonewaldL;Parent Project Muscular Dystrophy Bone Health Workshop Collaborators. Proceedings of a Parent Project Muscular Dystrophy Bone Health Workshop: morbidity due to osteoporosis in DMD: the path forward, May 12-13, 2016, Bethesda, Maryland, USA. Neuromuscul Disord. 2018;28(1):64–76.
13.
BushbyKFinkelRBirnkrantDJ, et al.Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol.2010;9(1):77–93.
14.
MendellJRMoxleyRTGriggsRC, et al.Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med.1989;320(24):1592–1597.
15.
GriggsRCMoxley 3rdRTMendellJR, et al.Prednisone in Duchenne dystrophy: a randomized, controlled trial defining the time course and dose response. Clinical investigation of Duchenne Dystrophy Group. Arch Neurol. 1991;48(4):383–388.
16.
GriggsRCMoxley 3rdRTMendellJR, et al.Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology. 1993;43(3 Pt 1):520–527.
17.
BalabanBMatthewsDJClaytonGHCarryT. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys Med Rehabil.2005;84(11):843–850.
18.
BiggarWDSkalskyAMcDonaldCM. Comparing deflazacort and prednisone in Duchenne muscular dystrophy. J Neuromuscul Dis. 2022;9(4):463–476.
19.
McDonaldCMSajeevGYaoZ, et al; ACT DMD Study Group and the Tadalafil DMD Study Group. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: a meta-analysis of disease progression rates in recent multicenter clinical trials. Muscle Nerve.2020;61(1):26–35.
20.
MardenJRFreimarkJYaoZSignorovitchJTianCWongBL. Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center. J Comp Eff Res. 2020;9(3):177–189.
21.
MillerLARomittiPACunniffC, et al.The Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): surveillance methodology. Birth Defects Res A Clin Mol Teratol. 2006;76(11):793–797.
22.
ZhangYMannJRJamesKA, et al.Duchenne and Becker muscular Dystrophies’ prevalence in MD STARnet surveillance sites: an examination of racial and ethnic differences. Neuroepidemiology. 2021;55(1):47–55.
23.
MathewsKDCunniffCKantamneniJR, et al.Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): case definition in surveillance for childhood-onset Duchenne/Becker muscular dystrophy. J Child Neurol. 2010;25(9):1098–1102.
24.
FoxDJKumarAWestNADiRienzoAGJamesKAOleszekJ; Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). Trends with corticosteroid use in males with Duchenne muscular dystrophy born 1982-2001. J Child Neurol. 2015;30(1):21–26.
25.
MannJRZhangYMcDermottS, et al.STARnet MD. Racial and ethnic differences in timing of diagnosis and clinical services received in Duchenne muscular dystrophy. Neuroepidemiology. 2023;57(2):90–99.
26.
WoodMLGrayRESKanisJAHarringtonCI. Deflazacort—a safer systemic steroid for the treatment of chronic dermatoses. Br J Dermatol.1985;113(s29):34–35.
27.
McDonaldCMMardenJRShiehPB, et al.Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status. J Comp Eff Res. 2023;12(4):e220190.
28.
WongBLCookTMillerH. Prednisone and deflazacort in Duchenne muscular dystrophy: a patient perspective and plain language summary publication of the Cincinnati study. J Comp Eff Res. 2022;11(11):779–786.
29.
ShiehPBElfringGTrifillisP, et al; Members of the Ataluren Phase IIb Study Group; Members of the Ataluren Phase IIb Study Clinical Evaluator Training Group; Members of the ACT DMD Study Group; Members of the ACT DMD Clinical Evaluator Training Group. Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy. J Comp Eff Res. 2021;10(18):1337–1347.
30.
GlossDMoxley 3rdRTAshwalSOskouiM. Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(5):465–472.
31.
ChrzanowskiSMPoudyalR. Deflazacort—new costs of an old medicine. JAMA Neurol. 2018;75(2):143–144.
32.
GuglieriMBushbyKMcDermottMP, et al.Effect of different corticosteroid dosing regimens on clinical outcomes in boys with Duchenne muscular dystrophy: a randomized clinical trial. JAMA. 2022;327(15):1456–1468.
33.
CowenLManciniMMartinALucasADonovanJM. Variability and trends in corticosteroid use by male United States participants with Duchenne muscular dystrophy in the Duchenne registry. BMC Neurol. 2019;19(1):84.
34.
KimSZhuYRomittiPA, et al.Associations between timing of corticosteroid treatment initiation and clinical outcomes in Duchenne muscular dystrophy. Neuromuscul Disord. 2017;27(8):730–737.
35.
McDonaldCMMayerOHHorKN, et al; PRO-DMD-01 consortium investigators. Functional and clinical outcomes associated with steroid treatment among non-ambulatory patients with Duchenne muscular Dystrophy1. J Neuromuscul Dis. 2023;10(1):67–79.
36.
ButterfieldRJKirkovSConwayKM, et al.Evaluation of effects of continued corticosteroid treatment on cardiac and pulmonary function in non-ambulatory males with Duchenne muscular dystrophy from MD STARnet. Muscle Nerve. 2022;66(1):15–23.
37.
BarnardAMRiehlSLWillcocksRJWalterGAAngellAMVandenborneK. Characterizing enrollment in observational studies of Duchenne muscular dystrophy by race and ethnicity. J Neuromuscul Dis. 2020;7(2):167–173.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
